Clinical Trial Update: Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy [Phase 2]

View source ↗

Summary

This phase 2 clinical trial update assesses the efficacy and safety of Besponsa (inotuzumab ozogamicin) in adults with Philadelphia-negative acute lymphoblastic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Philadelphia-negative Acute Lymphoblastic Leukemia

Drugs mentioned

• Besponsa (inotuzumab ozogamicin)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Acute Lymphocytic Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING